BAFF/APRIL標的治療薬 - 標的集団、競合情勢、市場予測（2034年）

主なハイライト

• TNFファミリーの主要メンバーであるBAFF/APRILは、受容体BAFF-R、TACI、BCMAを介してB細胞の生存と活性化を制御します。この軸の調節異常は、B細胞の過剰な活性化を通じて自己免疫疾患を引き起こします。BAFF/APRIL標的治療薬は、病原性B細胞応答を調節することによって免疫バランスを回復させることを目的としており、自己免疫疾患の活動性を低下させるという有望な臨床結果を示しています。
• BAFF/APRIL標的治療薬は、IgA腎症（IgAN）、ループス腎炎、重症筋無力症、全身性エリテマトーデス（SLE）、シェーグレン症候群、その他のB細胞を介する自己免疫疾患など、広範な自己免疫疾患に対処するために活発に開発されており、病原性B細胞の活性を調節し、患者の転帰を向上させる有望な新しい選択肢を提供しています。
• 主要7市場におけるIgANと診断された総患者数は、2024年に最大40万人です。
• 主要7市場のうち、ループス腎炎と診断された患者数がもっとも多いのは米国で、2024年に最大19万5,000人でした。
• 2025年5月、Vera Therapeuticsは、IgA腎症（IgAN）を対象としたataciceptの重要なフェーズIII ORIGIN 3試験の主要評価項目の結果が2025年第2四半期に出る見込みであり、2025年第4四半期に米国FDAに生物製剤承認申請（BLA）を提出し、早期承認を得る計画であることを発表しました。
• 2024年5月、Vera Therapeuticsは、米国FDAがIgAN治療薬としてataciceptにブレークスルーセラピー指定（BTD）を付与したと発表しました。この指定は、IgANを対象としたataciceptのフェーズIIb ORIGIN臨床試験から得られたデータの評価に基づき、ataciceptがIgAN患者に対する利用可能な治療法よりも臨床的に主要評価項目において実質的な向上を示す可能性があるというFDAの判断を反映したものです。
• 2024年11月、欧州医薬品庁（EMA）はIgAN治療薬としてataciceptを希少疾病用医薬品に指定しました。
• Telitaciceptは、重症筋無力症の治療薬として米国FDAから希少疾病用医薬品指定（ODD）とファストトラック指定（FTD）を受けています。

BAFF/APRIL標的治療薬市場の見通し

BAFF/APRIL標的治療薬の見通しは、自己免疫疾患における正確なB細胞調節という明確なアンメットニーズにより、急速に進行しています。2025年現在、このような融合タンパク質はFDA承認されていませんが、有望な候補が後期開発段階まで進んでいます。IgAN治療薬としてフェーズIII段階にあるAtacicept（Vera Therapeutics）はBTDを取得し、2025年後半のBLA申請、2026年の米国上市を目指しています。Telitacicept（RemeGen）は、重症筋無力症、SLE、シェーグレン症候群を対象とした米国の試験で評価中であり、ODDとFTDのサポートを受けています。さらに、AUR200（Aurinia Pharmaceuticals）は2024年後半にフェーズI試験を開始し、2025年に早期結果が出る見込みです。

これらの進歩は、BAFF/APRIL標的治療薬の情勢にとって非常に好ましいものであり、現在の治療の限界を克服し、治療困難な自己免疫疾患の患者に新たな希望をもたらす可能性のある、より効果的な二経路免疫療法へのシフトを示すものです。

当レポートでは、BAFF/APRIL標的治療薬の主要7市場（米国、ドイツ、スペイン、イタリア、フランス、英国、日本）について調査分析し、各地域の市場規模、現在の治療法、アンメットニーズ、新薬などの情報を提供しています。

目次

第1章 主な調査結果

第2章 レポートのイントロダクション

第3章 BAFF/APRIL標的治療薬のエグゼクティブサマリー

第4章 主な出来事

第5章 疫学と市場予測の調査手法

第6章 主要7市場のBAFF/APRIL標的治療薬市場の概要

• 市場シェアの分布：治療法別（2025年）
• 市場シェアの分布：治療法別（2034年）
• 市場シェアの分布：適応症別（2025年）
• 市場シェアの分布：適応症別（2034年）

第7章 BAFF/APRIL標的治療薬：背景と概要

• イントロダクション
• BAFF/APRIL標的治療薬のさまざまな適応症における可能性
• BAFF/APRIL標的治療薬の臨床応用

第8章 BAFF/APRIL標的治療薬の標的患者集団

• 前提条件と根拠
• 主な調査結果
• 主要7市場のBAFF/APRIL標的治療薬の適応症の総患者数
• 主要7市場のBAFF/APRIL標的治療薬の適応症の総患者集団
• 主要7市場のBAFF/APRIL標的治療薬の適応症における治療可能な総患者数

第9章 新しいBAFF/APRIL標的治療薬

• 主な競合
• Atacicept：Vera Therapeutics
• Telitacicept：RemeGen

第10章 BAFF/APRIL標的治療薬：主要7市場の分析

• 主な調査結果
• BAFF/APRIL標的治療薬の市場見通し
• BAFF/APRIL標的治療薬のコンジョイント分析
• BAFF/APRIL標的治療薬の主な市場予測の前提条件
  • コストの想定とリベート
  • 価格動向
  • アナログの評価
  • 上市年と治療法の普及
• 主要7市場のBAFF/APRIL標的治療薬の市場規模：適応症別
• 米国
  • 米国のBAFF/APRIL標的治療薬の総市場規模
  • 米国のBAFF/APRIL標的治療薬の市場規模：適応症別
  • 米国のBAFF/APRIL標的治療薬の市場規模：治療法別
• 欧州4ヶ国・英国
  • 欧州4ヶ国・英国のBAFF/APRIL標的治療薬の総市場規模
  • 欧州4ヶ国・英国のBAFF/APRIL標的治療薬の市場規模：適応症別
  • 欧州4ヶ国・英国のBAFF/APRIL標的治療薬の市場規模：治療法別
• 日本
  • 日本のBAFF/APRIL標的治療薬の総市場規模
  • 日本のBAFF/APRIL標的治療薬の市場規模：適応症別
  • 日本のBAFF/APRIL標的治療薬の市場規模：治療法別

第11章 SWOT分析

第12章 KOLの見解

第13章 アンメットニーズ

第14章 市場参入と償還

第15章 付録

第16章 DelveInsightのサービス内容

第17章 免責事項

第18章 DelveInsightについて

List of Tables

• Table 1: Target Population in the 7MM (2020-2034)
• Table 2: Marketed Drug Key cross
• Table 3: Product 1, Clinical Trial Description, 2024
• Table 4: Product 2, Clinical Trial Description, 2024
• Table 5: Emerging Drug Key cross
• Table 6: Product 1, Clinical Trial Description, 2024
• Table 7: Product 2, Clinical Trial Description, 2024
• Table 8: Total BAFF- and APRIL-targeted Therapies Market Size in the 7MM (2020-2034)
• Table 9: BAFF- and APRIL-targeted Therapies Market Size by Therapies in the 7MM (2020-2034)
• Table 10: BAFF- and APRIL-targeted Therapies Market Size by Indication in the 7MM (2020-2034)
• Table 11: Total BAFF- and APRIL-targeted Therapies Market Size in the United States (2020-2034)
• Table 12: BAFF- and APRIL-targeted Therapies Market Size by Therapies in the United States (2020-2034)
• Table 13: Total BAFF- and APRIL-targeted Therapies Market Size in EU4 and the UK (2020-2034)
• Table 14: BAFF- and APRIL-targeted Therapies Market Size by Therapies in EU4 and the UK (2020-2034)
• Table 15: Total BAFF- and APRIL-targeted Therapies Market Size in Japan (2020-2034)
• Table 16: BAFF- and APRIL-targeted Therapies Market Size by Therapies in Japan (2020-2034)

List of Figures

• Figure 1: Target Population in the 7MM (2020-2034)
• Figure 2: Total BAFF- and APRIL-targeted Therapies Market Size in the 7MM (2020-2034)
• Figure 3: BAFF- and APRIL-targeted Therapies Market Size by Therapies in the 7MM (2020-2034)
• Figure 4: BAFF- and APRIL-targeted Therapies Market Size by Indication in the 7MM (2020-2034)
• Figure 5: Total BAFF- and APRIL-targeted Therapies Market Size in the United States (2020-2034)
• Figure 6: BAFF- and APRIL-targeted Therapies Market Size by Therapies in the United States (2020-2034)
• Figure 7: Total BAFF- and APRIL-targeted Therapies Market Size in EU4 and the UK (2020-2034)
• Figure 8: BAFF- and APRIL-targeted Therapies Market Size by Therapies in EU4 and the UK (2020-2034)
• Figure 9: Total BAFF- and APRIL-targeted Therapies Market Size in Japan (2020-2034)
• Figure 10: BAFF- and APRIL-targeted Therapies Market Size by Therapies in Japan (2020-2034)

Key Highlights:

• BAFF and APRIL, key TNF family members, regulate B cell survival and activation via receptors BAFF-R, TACI, and BCMA. Dysregulation of this axis drives autoimmune diseases through excessive B cell activation. Therapies targeting BAFF/APRIL aim to restore immune balance by modulating pathogenic B cell responses and have shown promising clinical results in reducing autoimmune disease activity.
• BAFF and APRIL-targeted therapies are actively being developed to address a broad spectrum of autoimmune diseases, including IgA nephropathy (IgAN), lupus nephritis, myasthenia gravis, systemic lupus erythematosus (SLE), sjogren's syndrome, and other B cell-mediated autoimmune conditions, offering promising new options to modulate pathogenic B cell activity and improve patient outcomes.
• The total diagnosed prevalent population of IgAN in the 7MM comprised ~400,000 cases in 2024.
• Among the 7MM, the United States accounted for the highest number of diagnosed cases of lupus nephritis with ~195,000 cases in 2024.
• In May 2025, Vera Therapeutics announced that primary endpoint results from the pivotal Phase III ORIGIN 3 trial of atacicept in Immunoglobulin A Nephropathy (IgAN) are expected in Q2 2025, with plans to submit a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) in Q4 2025 for accelerated approval, targeting a potential PDUFA date and commercial launch in 2026.
• In May 2024, Vera Therapeutics announced that the US FDA has granted Breakthrough Therapy Designation (BTD) to atacicept for the treatment of IgAN. The designation reflects the FDA's determination that, based on an assessment of data from the Phase IIb ORIGIN clinical trial of atacicept for IgAN, atacicept may demonstrate substantial improvement on a clinically significant endpoint over available therapies for patients with IgAN.
• In November 2024, the European Medicines Agency (EMA) granted orphan medicine designation to Atacicept for the treatment of IgAN.
• Telitacicept has been granted Orphan Drug Designation (ODD) and Fast Track Designation (FTD) by the US FDA for the treatment of Myasthenia Gravis.

DelveInsight's "BAFF- and APRIL-targeted therapies - Target Population, Competitive Landscape, and Market Forecast - 2034" report delivers an in-depth understanding of the BAFF-and APRIL-targeted therapies, historical and competitive landscape as well as its market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The BAFF- and APRIL-targeted therapies' market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM BAFF- and APRIL-targeted therapies' market size from 2020 to 2034. The report also covers current BAFF- and APRIL-targeted therapies' treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

BAFF- and APRIL-targeted therapies Understanding and Treatment Algorithm

BAFF- and APRIL-targeted therapies Overview

BAFF and APRIL are members of the TNF family that play central roles in B cell survival, maturation, and immunoglobulin class switching through interactions with receptors BAFF-R, TACI, and BCMA. Dysregulation of the BAFF/APRIL axis contributes to autoimmune disease pathogenesis, as overexpression of these ligands can lead to excessive B cell activation and autoimmunity. BAFF predominantly signals through BAFF-R to activate both classical and alternative NF-κB pathways, while APRIL binds TACI and BCMA, also engaging heparan sulfate proteoglycans to enhance B cell responses. The critical role of BAFF/APRIL in immune regulation has made them attractive therapeutic targets, with clinical trials demonstrating that BAFF blockade can effectively reduce disease activity in several autoimmune disorders. Targeted therapies against these ligands aim to restore immune balance by modulating pathogenic B cell responses.

BAFF- and APRIL-targeted Therapies Market Overview

BAFF- and APRIL-targeted therapies are emerging as promising treatments across multiple autoimmune diseases, including IgA nephropathy, lupus nephritis, myasthenia gravis, systemic lupus erythematosus, and Sjogren's syndrome. Their development signals a positive shift in the autoimmune treatment landscape, potentially expanding therapeutic options and driving growth across these high-need indication markets.

BAFF- and APRIL-targeted Therapies Epidemiology

The epidemiology chapter of BAFF- and APRIL-targeted therapies in the report provides historical as well as forecasted epidemiology segmented as total cases in selected indications for BAFF- and APRIL-targeted therapies, total eligible patient pool in selected indications for BAFF- and APRIL-targeted therapies, and total treated cases in selected indications for BAFF- and APRIL-targeted therapies in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034.

• The total diagnosed prevalent population of IgA nephropathy in the 7MM comprised ~400,000 cases in 2024.
• As per the analysis, IgA Nephropathy shows male predominance, with ~60% cases of IgAN in males and ~40% cases in females, in 2024, in the US.
• Among the 7MM, Japan accounted for the highest number of diagnosed prevalent cases of IgA nephropathy, i.e., ~45% of the total population in 2024.
• Among the 7MM, the United States accounted for the highest number of diagnosed cases of Lupus Nephritis with ~195,000 cases in 2024.
• In 2024, Class IV accounted for the highest number of cases of Lupus Nephritis in the US and this trend is likely to remain the same.
• It was observed that SLE occurs majorly in the age group of 40-59 years.
• Among EU4 and the UK, the United Kingdom accounted for the highest diagnosed prevalent cases of Sjogren's syndrome, whereas Spain accounted for the least number of cases.

BAFF- and APRIL-targeted therapies Drug Chapters

The drug chapter segment of the BAFF- and APRIL-targeted therapies report encloses a detailed analysis of approved BAFF- and APRIL-targeted therapies, late-stage (Phase III and Phase II) BAFF- and APRIL-targeted therapies. It also helps understand the clinical trial details of BAFF- and APRIL-targeted therapies, expressive pharmacological action, agreements and collaborations, approval, and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Marketed BAFF- and APRIL-targeted therapies

As of 2025, no BAFF/APRIL-targeting fusion protein is FDA-approved, highlighting a significant gap in therapies directly modulating B cell survival via dual ligand inhibition. Current treatment options primarily focus on single-target approaches or broader immunosuppression. Emerging fusion proteins like Atacicept, Telitacicept, and AUR200 aim to meet this unmet need by offering a more targeted strategy to reduce disease-driving B cell activity in autoimmune conditions, potentially improving efficacy and minimizing off-target effects.

Emerging BAFF- and APRIL-targeted therapies

Atacicept: Vera Therapeutics

Atacicept is an investigational recombinant fusion protein that contains the soluble transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) receptor that binds to the cytokines BAFF and APRIL. These cytokines are members of the TNF family that promote B-cell survival and autoantibody production associated with certain autoimmune diseases, including IgAN and lupus nephritis. Vera believes atacicept is positioned for best-in-class potential, targeting B cells and plasma cells to reduce autoantibodies and having been administered to more than 1,500 patients in clinical studies across different indications. Currently, atacicept is in Phase III of the development process for IgAN.

Telitacicept: RemeGen

Telitacicept is a fusion protein targeting both BAFF and APRIL, developed by RemeGen for B cell-mediated autoimmune diseases. It is currently in global clinical trials, including in the United States, for myasthenia gravis, SLE, and Sjogren's syndrome. In the US, telitacicept has been granted ODD and FTD by the US FDA for the treatment of Myasthenia Gravis. Notably, in August 2024, the first US patient was enrolled in a global Phase III trial for generalized myasthenia gravis, marking a significant milestone in its clinical development.

BAFF- and APRIL-targeted therapies Market Outlook

The therapeutic landscape for BAFF- and APRIL-targeted therapies is evolving rapidly, driven by a clear unmet need for precise B cell modulation in autoimmune diseases. As of 2025, no such fusion proteins are FDA-approved, but promising candidates are progressing through late-stage development. Atacicept (Vera Therapeutics), in Phase III for IgAN, has secured BTD and is on track for a BLA submission in late 2025, with a potential US launch in 2026. Telitacicept (RemeGen) is being evaluated in US trials for myasthenia gravis, SLE, and Sjogren's syndrome, supported by ODD and FTD, with pivotal data due in mid-2025. Additionally, AUR200 (Aurinia Pharmaceuticals) began Phase I trials in late 2024, with early results expected in 2025.

These advancements are highly positive for the BAFF/APRIL-targeted therapy landscape, signaling a shift toward more effective, dual-pathway immunotherapies that may overcome the limitations of current treatments and offer new hope for patients with difficult-to-treat autoimmune diseases.

BAFF- and APRIL-targeted therapies Drugs Uptake

This section focuses on the uptake rate of potential approved and emerging BAFF- and APRIL-targeted therapies expected to be launched in the market during 2025-2034.

BAFF- and APRIL-targeted therapies Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I. It also analyzes key players involved in developing targeted therapeutics. The presence of numerous drugs under different stages is expected to generate immense opportunity for BAFF- and APRIL-targeted therapies market growth over the forecast period.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for BAFF- and APRIL-targeted therapies.

KOL Views

To keep up with current and future market trends, we take Industry Experts' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on BAFF- and APRIL-targeted therapies' evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along challenges related to accessibility.

DelveInsight's analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as Washington University and others.

Their opinion helps understand and validate current and emerging therapy treatment patterns or BAFF- and APRIL-targeted therapies market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial's primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

Reimbursement may be referred to as the negotiation of a price between a manufacturer and payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health Technology Assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug.

In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs including Medicare, Continuing Medical Education (CME) program, the Children's Health Insurance Program (CHIP), and the state and federal health insurance marketplaces are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs), and third-party organizations that provide services, and educational programs to aid patients are also present.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Key Updates on BAFF- and APRIL-targeted therapies

• In May 2025, Vera Therapeutics announced that primary endpoint results from the pivotal Phase III ORIGIN 3 trial of atacicept in IgAN are expected in Q2 2025, with plans to submit a BLA to the US FDA in Q4 2025 for accelerated approval, targeting a potential PDUFA date and commercial launch in 2026.
• In November 2024, EMA granted Orphan medicine designation to Atacicept for the treatment of IgAN.
• In September 2024, the first participant was dosed in a Phase I study of AUR 200, a differentiated, potential best-in-class therapy for autoimmune diseases that targets both BAFF and APRIL. The Company continues to expect to report initial results from this study in the first half of 2025.
• In May 2024, Vera Therapeutics announced that the US FDA has granted BTD to atacicept for the treatment of IgAN. The designation reflects the FDA's determination that, based on an assessment of data from the Phase IIb ORIGIN clinical trial of atacicept for IgAN, atacicept may demonstrate substantial improvement on a clinically significant endpoint over available therapies for patients with IgAN.

The abstract list is not exhaustive and will be provided in the final report.

Scope of the Report:

• The report covers a segment of key events, an executive summary, and a descriptive overview of the BAFF- and APRIL-targeted therapies, explaining its mechanism, and therapies (current and emerging).
• Comprehensive insight into the competitive landscape, and forecasts, the future growth potential of treatment rate, drug uptake, and drug information have been provided.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current landscape.
• A detailed review of the BAFF- and APRIL-targeted therapies market, historical and forecasted market size, and market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis, expert insights/KOL views, and treatment preferences that help shape and drive the 7MM BAFF- and APRIL-targeted therapies market.

BAFF- and APRIL-targeted therapies Report Insights

• BAFF- and APRIL-targeted therapies Targeted Patient Pool
• Therapeutic Approaches
• BAFF- and APRIL-targeted therapies Pipeline Analysis
• BAFF- and APRIL-targeted therapies Market Size and Trends
• Existing and future Market Opportunities

BAFF- and APRIL-targeted therapies Report Key Strengths

• 10 years Forecast
• The 7MM Coverage
• Key Cross Competition
• Drugs Uptake and Key Market Forecast Assumptions

BAFF- and APRIL-targeted therapies Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT)

Key Questions:

• What was the total market size of BAFF- and APRIL-targeted therapies, the market size by therapies, market share (%) distribution, and what would it look like in 2034? What are the contributing factors for this growth?
• Which drug is going to be the largest contributor in 2034?
• Which is the most lucrative market for BAFF- and APRIL-targeted therapies?
• What are the pricing variations among different geographies for approved therapies?
• How the reimbursement landscape has for BAFF- and APRIL-targeted therapies evolved since the first one was approved? Do patients have any access issues that are driven by reimbursement decisions?
• What are the risks, burdens, and unmet needs of treatment with BAFF- and APRIL-targeted therapies? What will be the growth opportunities across the 7MM for the patient population of BAFF- and APRIL-targeted therapies?
• What are the key factors hampering the growth of the market for BAFF- and APRIL-targeted therapies?
• What are the indications for which recent novel therapies and technologies have been developed to overcome the limitations of existing treatments?
• What key designations have been granted to the therapies for BAFF- and APRIL-targeted therapies?
• What is the cost burden of approved therapies on the patient?
• Patient acceptability in terms of preferred therapy options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies?

Reasons to buy:

• The report will help develop business strategies by understanding the latest trends and changing dynamics driving the BAFF- and APRIL-targeted therapies market.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of indication-wise current and emerging therapies under the conjoint analysis section to provide visibility around leading indications.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of BAFF- and APRIL-targeted therapies

4. Key Events

5. Epidemiology and Market Forecast Methodology

6. BAFF- and APRIL-targeted Therapies Market Overview at a Glance in the 7MM

• 6.1. Market Share (%) Distribution by Therapies in 2025
• 6.2. Market Share (%) Distribution by Therapies in 2034
• 6.3. Market Share (%) Distribution by Indications in 2025
• 6.4. Market Share (%) Distribution by Indications in 2034

7. BAFF- and APRIL-targeted therapies: Background and Overview

• 7.1. Introduction
• 7.2. Potential of BAFF- and APRIL-targeted therapies in Different Indications
• 7.3. Clinical Applications of BAFF- and APRIL-targeted therapies

8. Target Patient Pool of BAFF- and APRIL-targeted therapies

• 8.1. Assumptions and Rationale
• 8.2. Key Findings
• 8.3. Total Cases of Selected Indication for BAFF- and APRIL-targeted therapies in the 7MM
• 8.4. Total Eligible Patient Pool of Selected Indication for BAFF- and APRIL-targeted therapies in the 7MM
• 8.5. Total Treatable Cases in Selected Indication for BAFF- and APRIL-targeted therapies in the 7MM

9. Emerging BAFF- and APRIL-targeted therapies

• 9.1 Key Competitors
• 9.2 Atacicept: Vera Therapeutics
  • 9.2.1 Product Description
  • 9.2.2 Other Developmental Activities
  • 9.2.3 Clinical Development
  • 9.2.4 Safety and Efficacy
  • 10.2.5. Analyst Views
• 9.3 Telitacicept: RemeGen
  • 9.3.1 Product Description
  • 9.3.2 Other Developmental Activities
  • 9.3.3 Clinical Development
  • 9.3.4 Safety and Efficacy
  • 9.3.5. Analyst Views

10 BAFF- and APRIL-targeted therapies: Seven Major Market Analysis

• 10.1 Key Findings
• 10.2 Market Outlook of BAFF- and APRIL-targeted therapies
• 10.3 Conjoint Analysis of BAFF- and APRIL-targeted therapies
• 10.4 Key Market Forecast Assumptions of BAFF- and APRIL-targeted therapies
  • 10.4.1 Cost Assumptions and Rebates
  • 10.4.2 Pricing Trends
  • 10.4.3 Analogue Assessment
  • 10.4.4 Launch Year and Therapy Uptakes
• 10.5 Total Market Size of BAFF- and APRIL-targeted therapies by Indications in the 7MM
• 10.6 The United States
  • 10.6.1 Total Market Size of BAFF- and APRIL-targeted therapies in the United States
  • 10.6.2 Market Size of BAFF- and APRIL-targeted therapies by Indication in the United States
  • 10.6.3 Market Size of BAFF- and APRIL-targeted therapies by Therapies in the United States
• 10.7 EU4 and the UK
  • 10.7.1 Total Market Size of BAFF- and APRIL-targeted therapies in EU4 and the UK
  • 10.7.2 Market Size of BAFF- and APRIL-targeted therapies by Indications in EU4 and the UK
  • 10.7.3 Market Size of BAFF- and APRIL-targeted therapies by Therapies in EU4 and the UK
• 10.8 Japan
  • 10.8.1 Total Market Size of BAFF- and APRIL-targeted therapies in Japan
  • 10.8.2 Market Size of BAFF- and APRIL-targeted therapies by Indications in Japan
  • 10.8.3 Market Size of BAFF- and APRIL-targeted therapies by Therapies in Japan

11 SWOT Analysis

12 KOL Views

13 Unmet Needs

14 Market Access and Reimbursement

15 Appendix

• 15.1 Bibliography
• 15.2 Report Methodology

16 DelveInsight Capabilities

17 Disclaimer

18 About DelveInsight